Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Monica Abbott

Physician Assistant, Medical Tulsa, OK Physician Assistant

NPI 1598975559 CMS profile 117956

7901 S Sheridan Rd, Tulsa, OK 74133

Open in the dashboard

General payments

$11,325

504 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Monica Abbott of Tulsa, OK is reported in the CMS Open Payments database as having received $11,325 across 504 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,046 148
2024 General $3,290 137
2023 General $1,623 77
2022 General $1,961 81
2021 General $1,405 61

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Monica Abbott
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Monica Abbott were reported at $3,046. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Monica Abbott Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $1,405 $156 $41–$563 $132
2022 $1,961 $185 $55–$649 $149
2023 $1,623 $199 $58–$717 $160
2024 $3,290 $206 $62–$740 $164
2025 $3,046 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. E.R. Squibb & Sons, L.L.C. $1,717 45 payments
  2. Pfizer Inc. $1,337 59 payments
  3. AbbVie, Inc. $1,302 57 payments
  4. Janssen Biotech, Inc. $854 32 payments
  5. Lilly USA, LLC $752 37 payments
  6. Novartis Pharmaceuticals Corporation $714 35 payments
  7. Regeneron Healthcare Solutions, Inc. $711 30 payments
  8. Sun Pharmaceutical Industries Inc. $689 31 payments
  9. UCB, Inc. $594 29 payments
  10. Arcutis Biotherapeutics, Inc. $581 32 payments
  11. Other $2,074 117 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $10,996 497 payments
  2. Education $328 7 payments
Products named General payments · program years 2021–2025
  1. CIBINQO $1,042 49 payments
  2. SOTYKTU $1,016 35 payments
  3. TREMFYA $823 30 payments
  4. TALTZ $682 36 payments
  5. LITFULO $645 32 payments
  6. SKYRIZI $586 24 payments
  7. Zoryve $567 31 payments
  8. EUCRISA $473 28 payments
  9. RINVOQ $465 23 payments
  10. Bimzelx $462 22 payments
  11. Other $5,003 253 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 20 drugs

Part D claims

837

Median for Physician Assistant: 241

Drug cost

$1,226,444

Median for Physician Assistant: $4,110

Branded share of claims

18.8%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Humira(Cf) Pen Adalimumab Brand 42 $414,547
Skyrizi Pen Risankizumab-Rzaa Brand 14 $288,736
Tremfya Guselkumab Brand 12 $172,650
Dupixent Pen Dupilumab Brand 34 $122,580
Otezla Apremilast Brand 23 $121,905
Cosentyx Sensoready (2 Pens) Secukinumab Brand 12 $87,129
Tacrolimus Generic 22 $2,879
Ketoconazole Generic 142 $2,745
Clobetasol Propionate Generic 51 $2,668
Fluorouracil Generic 41 $2,480

The 10 drugs with the highest cost, of 20 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 60 billing codes

Paid by Medicare

$104,989

Of which drugs: $2,202

Medicare patients

870

Average age 75

Services billed

2,494

487 women, 383 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 74%
Arthritis 43%
Diabetes 25%
Ischemic heart disease 22%
Chronic kidney disease 18%
Atrial fibrillation 16%
Depression 14%
Cancer 13%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 27 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
SOTYKTU
  • E.R. Squibb & Sons, L.L.C. $515
$515 — —
SKYRIZI
  • AbbVie, Inc. $253
$253 14 —
Zoryve
  • Arcutis Biotherapeutics, Inc. $247
$247 — —
TREMFYA
  • Janssen Biotech, Inc. $238
$238 12 —
Bimzelx
  • UCB, Inc. $229
$229 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 27 with Patron

Records

504 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Oklahoma

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record